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Elevated TMEM106B levels exaggerate
lipofuscin accumulation and lysosomal
dysfunction in aged mice with progranulin
deficiency
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Abstract
Mutations resulting in haploinsufficiency of progranulin (PGRN) cause frontotemporal lobar degeneration with
TDP-43-positive inclusions (FTLD-TDP), a devastating neurodegenerative disease. Accumulating evidence suggest a
crucial role of progranulin in maintaining proper lysosomal function during aging. TMEM106B has been identified as a
risk factor for frontotemporal lobar degeneration with progranulin mutations and elevated mRNA and protein levels of
TMEM106B are associated with increased risk for frontotemporal lobar degeneration. Increased levels of TMEM106B
alter lysosomal morphology and interfere with lysosomal degradation. However, how progranulin and TMEM106B
interact to regulate lysosomal function and frontotemporal lobar degeneration (FTLD) disease progression is still
unclear. Here we report that progranulin deficiency leads to increased TMEM106B protein levels in the mouse cortex
with aging. To mimic elevated levels of TMEM106B in frontotemporal lobar degeneration (FTLD) cases, we generated
transgenic mice expressing TMEM106B under the neuronal specific promoter, CamKII. Surprisingly, we found that the
total protein levels of TMEM106B are not altered despite the expression of the TMEM106B transgene at mRNA and
protein levels, suggesting a tight regulation of TMEM106B protein levels in the mouse brain. However, progranulin
deficiency results in accumulation of TMEM106B protein from the transgene expression during aging, which is
accompanied by exaggerated lysosomal abnormalities and increased lipofuscin accumulation. In summary, our mouse
model nicely recapitulates the interaction between progranulin and TMEM106B in human patients and supports a
critical role of lysosomal dysfunction in the frontotemporal lobar degeneration (FTLD) disease progression.
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Background
Frontotemporal lobar degeneration (FTLD) is a devastating
neurodegenerative disease that affects approximately
250,000 people in the United States [24, 28]. Clinical symp-
toms of FTLD include behavioral abnormalities, personality
changes, and language impairments [25]. A major type of
FTLD shows TDP-43 and ubiquitin positive inclusions
(FTLD-TDP) [3, 26]. Progranulin (PGRN) haploinsuffi-
ciency due to mutations in the Progranulin gene (GRN) is
one of the major causes of FTLD-TDP [4, 11, 17].
Additional environmental or genetic factors influence
the manifestation of FTLD-TDP, resulting in a high vari-
ability in age of onset and pathological presentation,
even with identical mutations [42]. Recent genome-wide
association studies by several groups have identified
TMEM106B, a gene encoding a type II transmembrane
protein of unknown function, as a bona fide risk factor
for FTLD-TDP, especially in patients with PGRN muta-
tions [10, 13, 15, 41, 43]. The TMEM106B risk allele was
reported to increase TMEM106B mRNA levels [41].
Both mRNA and protein levels of TMEM106B are ele-
vated in FTLD-TDP patients, especially in PGRN mutant
carriers [7]. These data suggest that PGRN might regu-
late TMEM106B protein homeostasis and elevated
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TMEM106B levels increase the risk for FTLD-TDP with
PGRN mutations.
Our recent studies and others showed that
TMEM106B is highly expressed in neurons, mainly lo-
calizes in the late endosome/lysosome compartments,
and regulates lysosomal morphology [6, 7, 20, 21, 36].
Overexpression of TMEM106B results in accumulation
of enlarged lysosomes and delays the degradation of
endocytic cargoes, such as EGFR [6]. More recently,
TMEM106B was shown to interact with MAP6 to con-
trol lysosomal trafficking in dendrites and decreased
levels of TMEM106B result in defects in lysosome size,
mobility and lysosomal trafficking in neurons [33, 36].
These observations strongly argue that proper regulation
of TMEM106B levels is critical for normal lysosomal
function and that impaired lysosomal function due to el-
evated TMEM106B levels might accelerate the develop-
ment of FTLD phenotypes. Along this line, several
recent studies have suggested a critical role of PGRN in
lysosomes. Human patients with a total loss of PGRN
exhibit neuronal ceroid lipofuscinosis (NCL) [35], a lyso-
somal storage disease characterized by the accumulation
of auto-fluorescent storage material (lipofuscin). NCL
phenotypes and lysosomal abnormalities were also seen
in PGRN knockout mice [1, 18, 38]. Furthermore, PGRN
is transcriptionally co-regulated with a number of essen-
tial lysosomal genes [5], and we have demonstrated that
PGRN is a lysosomal resident protein delivered to lyso-
somes through two independent mechanisms [19, 46].
Finally, FTLD-TDP/PGRN patients also exhibit typical
pathological features of NCL pathology [18], suggesting
FTLD and NCL caused by PGRN mutations are patho-
logically linked. Thus the identification of TMEM106B
as a risk factor for FTLD with PGRN mutations and the
fact that increased TMEM106B levels impair lysosomal
function further underscore lysosomal dysfunction as
one of the disease mechanisms for FTLD.
To determine an in vivo effect of elevated TMEM106B
levels in mouse models, we generated transgenic lines ex-
pressing human TMEM106B under a neuronal specific
promoter. To our surprise, we found that TMEM106B
protein levels are tightly regulated despite the expression
of the transgene at RNA and protein level. However, ele-
vated TMEM106B levels were detected in aged PGRN de-
ficient mice expressing the transgene, which exacerbates
the lysosomal abnormality and lipofuscin accumulation in
the PGRN deficient background. Thus our data nicely il-
lustrates the cross-regulation between PGRN and
TMEM106B during aging and neurodegeneration.
Methods
Pharmacological reagents and antibodies
The following antibodies were used in this study: rat anti-
mouse LAMP1 (1D4B) from BD Biosciences, goat anti-
mouse Cathepsin D (C-20) from Santa Cruz and mouse
anti-beta III tubulin from Promega. Rabbit anti-subunit c
of mitochondrial ATP synthase (SCMAS) antibodies [32]
were a gift from Dr. Elizabeth F. Neufeld (David Geffen
School of Medicine, University of California, Los Angeles,
CA). Rabbit anti-TMEM106B antibodies were generated
against the cytosolic domain of human TMEM106B as
previously described [6].
Mouse strains
Human TMEM106B cDNAs with polyA sequence from
the pEGFP-C1 vector were amplified and cloned into
the pMM403 plasmid from Addgene (plasmid 34926)
using the NotI restriction site. The expression cassette
was excised by digestion with the restriction enzyme SfiI
and injected into the pronuclei of fertilized eggs derived
from FVB/NJ strain by the Transgenic Mouse Facility at
Cornell University to yield offspring with different ex-
pression levels of TMEM106B. 16 pups were born after
one round of injection and implantation. The founder
#2 with the highest TMEM106B was selected and back
crossed with wild type C57/BL6 for three generation for
experimental analysis. Wild type C57/BL6 and PGRN
−/− mice were obtained from Jackson Laboratories. All
mice were housed in the Weill Hall animal facility.
Genotyping
Genomic DNA was extracted from mouse tails using the
REDextract kit from Sigma. Primers with sequences
5’TCCAACCCCCTCAGTACATC3’ and 5’TTTTCTTG
CCCCCTAGGAAT3’ were used to identify human
TMEM106B transgene (594 bp PCR product). Notch
primers (5’ GATATC GTGGTGCATACCCTCCTG3’
and 5’ GTGGTCTAGGATGCTTGGGTCTAG 3’) were
used to amplify Notch1 as an internal control (300 bp
PCR product). Progranulin deficient mice were geno-
typed using the mixture of following primers: 5’
AGAGGGTGAGCTGCAATGTT 3’, 5’AAGGGCATTA
GCCAAGTGTG3’ and 5’TCTCCCAGGTAGCCCCTAC
T3’ in which wild type has a 468 bp product and PGRN
−/− has a 211 bp PCR product.
Western blot analysis
Cortices were homogenized in RIPA buffer on ice and an
equal volume of 2X SDS sample buffer was added before
sonication. Samples were maintained on ice throughout
before loading on SDS-PAGE. TMEM106B protein runs
as a dimer under this condition (Additional file 1) [7].
Western blots were done as previously described [6].
TMEM106B protein levels were quantified using LiCor
Odyssey system and normalized to beta III tubulin.
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qPCR analysis
mRNAs were extracted from cortices using TRIZOL (Invi-
trogen). mRNAs were reversed transcribed to cDNAs
using iScript kit (Biorad). Real time PCRs were done on
Roche Lifecycler 480 using the following primers: mouse
actin (5’ACGAGGCCCAGAGCAAGAG3’ and 5’TCTCC
AAGTCGTCCCAGTTG3’), mouse TMEM106B 5’CGC
GTGCGGTTTCTAGAGCAT 3’ and 5’CCTCCCCGGG
CTCTCAATGT3’) and human TMEM106B (5’GGGC
AAGAAAACCAACTGGTGGC3’ and 5’ TCACGTCGA-
TAGAGCGAGGGAA 3’). All the primers have the ampli-
fication efficiency close to 100%. Transcript levels were
calculated using efficiency-adjusted ΔΔ-CT. All tran-
scripts were normalized to actin.
Mass spectrometry analysis
Cortices were dissected from TMEM106B transgenic mice
at 1.5 months old and lysed in 50 mM Tris, 150 mM NaCl
and 1% Triton plus protease inhibitors (Roche). After cen-
trifugation, the supernatant was immunoprecipitated with
Affigel (Biorad) conjugated with anti-TMEM106B anti-
bodies. 2% of the IP products were eluted, trypsinized and
analyzed by mass spec as previously described [19, 46].
Immunofluorescence microscopy
Mouse brains were perfused and fixed with 4% formal-
dehyde. After gradient dehydration with 15% and 30%
sucrose, the mouse brains were embedded with OCT
compound (Sakura Finetek USA) and sliced with Cryo-
tome. For immunostaining (not for lipofuscin analysis),
brain sections were incubated with 0.01% Sudan Black B
(Spectrum Chemical) in 70% ethanol at room
temperature for 20 min to negate the autofluorescence,
then permeabilized and blocked in blocking buffer
(0.05% saponin, 3% BSA in TBS) for 1 h. Primary anti-
bodies were incubated in blocking buffer overnight at 4 °
C. Sections were washed and incubated in secondary
antibodies conjugated to Alexaflour 488, 568, or 660
(Invitrogen). Sections were washed three more times
and coverslips mounted onto slides with Fluoromount G
(Southern Biotech). Images were acquired on a CSU-X
spinning disc confocal microscope (Intelligent Imaging
Innovations) with an HQ2 CCD camera (Photometrics)
using a 40x or 100x objective.
Quantification of enlarged lysosomes and lipofuscin
For the quantification of enlarged lysosomes, the lyso-
somes were visualized by anti-LAMP1 staining, and the
entire neuron somas were captured using Z stack. Neu-
rons with enlarged lysosomes (diameter > 1.0 μm) were
counted. It should be noted that during fixation, lyso-
somal size and area might have been changed but we al-
ways have a control group and experimental group
analyzed at the same time. For lipofuscin analysis, brain
sections were stained with Hochest 33324 solution
(Thermo Fisher Scientific) after permeabilization and
blocking. Images were acquired on an epifluorescence
microscope (Zeiss) equipped with a CCD camera. Auto
fluorescent signals were quantified using Image J (NIH).
Statistical analysis
The data were presented as mean ± SEM. Statistical signifi-
cance between multiple groups was analyzed by one-way
ANOVA followed by Bonferroni’s multiple comparison test.
Two-group analysis was performed using the Student’s t
test. P-values <0.05 were considered statistically significant.
All statistical analyses were performed using GraphPad
Prism 5 software (GraphPad Software).
Results
Generation of TMEM106B transgenic mice
Since elevated TMEM106B levels increase the risk of
FTLD with PGRN mutations, transgenic mice with
TMEM106B overexpression would allow us to under-
stand the consequences of TMEM106B overexpression
Fig. 1 Generation of TMEM106B transgenic mice. a Schematic drawing
of the expression construct used to inject the pronuclei of fertilized eggs.
Human TMEM106B and poly A sequence were cloned into the NotI site
of pMM403 and the cassette was excised with SfiI for injection. b qPCR
analysis of mouse TMEM106B and human TMEM106B mRNA levels in
the offspring of highly expressed transgenic line and WT littermate
controls of 4–5 months of age. Relative mRNA levels are normalized to
actin. n= 3, student’s t-test, *, p< 0.01. c Mass spectrometry analysis of
TMEM106B from the transgenic line. TMEM106B protein was
immunoprecipitated from the cortical lysates of the transgenic line and
the IP product was trypsin digested and subject to mass spec analysis
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in animal models. Our preliminary data suggest that
TMEM106B is highly expressed in neurons and that
overexpression of TMEM106B in neuronal cell lines
results in enlarged lysosomes and lysosomal dysfunc-
tion [6]. Given these preliminary findings, we gener-
ated constructs expressing human TMEM106B cDNA
under the neuron specific promoter, CaMKII alpha
[23] (Fig. 1a). Our previous studies have shown that
fusion of an epitope tag on TMEM106B often leads
to changes in TMEM106B localization and function
[6]. Thus we decided to express a human TMEM106B
transgene without an epitope tag. The expression cas-
sette was injected into the pronuclei of fertilized eggs
derived from an FVB/NJ strain. Initial screening using
primers specific for the transgene identified 3 positive
pups containing different copy numbers of the trans-
genic construct (data not shown). These pups were
further crossed with wild type C57/BL6 and the ex-
pression of transgenes was analyzed by real time PCR
in the cortex of offspring at weaning age when the
CamKII promoter is active [23]. For the rest of the
study, we focused on the highest expression line #2.
When normalized to actin, the human TMEM106B
gene appears to be expressed at mRNA level close to
3 fold that of endogenous mouse TMEM106B in line
#2 (Fig. 1b). The expression of human TMEM106B
transgene does not seem to affect the RNA levels of
endogenous mouse TMEM106B (Fig. 1b). Due to the
high sequence similarity between mouse and human
TMEM106B (Additional file 2), our home made anti-
human TMEM106B antibodies also recognize mouse
TMEM106B. To examine whether human
TMEM106B protein is expressed in the transgenic
lines, we immunoprecipitated (IP) TMEM106B from
the cortical lysates of transgenic TMEM106B mice
and determined the presence of human specific pep-
tides by mass spectrometry. Human specific peptides
are clearly detectable in trypsin digested IP products
from the transgenic lines (Fig. 1c), suggesting that the
human transgene is expressed at both mRNA and
protein levels.
Tight regulation of TMEM106B protein levels in the
transgenic line
Next we determined the TMEM106B protein levels in
the transgenic line using our polyclonal anti-human
TMEM106B antibodies which recognize both human
and mouse TMEM106B. Despite expression of the
TMEM106B transgene at both mRNA and protein levels
(Fig. 1b and c), we failed to detect an increase of total
TMEM106B protein levels in the transgenic line (Fig. 2a).
Aging is the biggest risk factor for neurodegenerative
diseases, including FTLD. Lysosomal activities, which
regulate TMEM106B turnover [6, 7, 21], are known to
decline during aging. Therefore we asked whether we
can detect increased TMEM106B protein levels in the
Fig. 2 TMEM106B protein levels are tightly regulated in the mouse cortex. (a, b) TMEM106B protein levels are not changed in the transgenic
mice of 4–5 months of age (a) or 17-20months of age (b). Cortical lysates from the transgenic and littermate controls were subjected to Western
blot with anti- TMEM106B antibodies. n = 3, student’s t-test. ns, no significance
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aged brain in the transgenic mice compared to littermate
controls. Again, we failed to see any increase in
TMEM106B protein levels in the aged transgenic mice
(Fig. 2b). These results strongly suggest that the level of
TMEM106B protein is tightly regulated in both young
and aged mouse brain.
Progranulin deficiency leads to increased TMEM106B
levels in the aged mice
Since TMEM106B was first identified as a risk factor
specific for PGRN mutant carriers [10, 15, 41, 43], we
determined whether PGRN regulates the homeostasis of
TMEM106B protein levels during aging. TMEM106B
protein levels in the cortex do not show any detectable
changes with aging in the wild type mice (Fig. 3a), but
PGRN deficiency leads to significant increase of cortical
TMEM106B protein levels with aging (Fig. 3a, b). Con-
sistent with this result, TMEM106B protein levels in the
cortex do not differ in the age matched young wild type
or PGRN−/− mice (4–5 month old) (Fig. 3c) but are sig-
nificantly increased in aged PGRN−/− mice compared to
wild type controls (Fig. 3c), suggesting a role of PGRN
in maintaining TMEM106B homeostasis during aging.
Previously, PGRN deficiency has been reported to result
in increased TMEM106B protein levels in both young
and old mice [18]. Although the cause of the discrepancy
is not clear, it might be explained by strain difference.
Next, we examined the levels of TMEM106B protein
in PGRN−/− mice expressing the TMEM106B transgene.
While expression of the TMEM106B transgene did not
lead to an increase in TMEM106B protein levels in the
cortex of young adult mice with PGRN deficiency
(Fig. 4a), a significant increase in the TMEM106B pro-
tein levels was detected in aged PGRN−/− mice express-
ing the transgene compared to PGRN−/− controls in
aged brain (Fig. 4b). This strongly argues for a regulation
of TMEM106B protein homeostasis by PGRN in the
aged brain.
Expression of TMEM106B transgene exacerbates
lysosomal abnormalities of PGRN deficient mice
Lipofuscin accumulation is an indicator of lysosomal dys-
function and a hallmark for NCL disease. Increased accu-
mulation of lipofuscin has been reported in NCL patients
with PGRN loss [35] and in PGRN−/− mice [1, 38]. Con-
sistent with these previous studies, we observed a
Fig. 3 Regulation of TMEM106B protein levels by PGRN in aged brain. a Endogenous TMEM106B protein levels are elevated in PGRN−/− mice
but not in wild type mice upon aging. Cortical lysates from mice of indicated genotypes and ages (young: 4–5 months; aged: 17–20 months old)
were subjected to Western blot with anti- TMEM106B antibodies. b Quantification of (a) to compare TMEM106B protein levels between young
and aged mice in the WT (left) or GRN−/− (right) background. c Quantification of TMEM106B protein levels between WT and GRN−/− mice
during young or aged conditions. n = 3-5, student’s t-test. *, p < 0.05; **, p < 0.01. ns, no significance
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significant increase of lipofuscin in both the cortex and
thalamus of the aged PGRN−/− mouse brains (Fig. 5a-c).
The lipophilic subunit c of the mitochondrial ATP synthase
(SCMAS) is a main component of lipofuscin detected in
many NCL patients [9], and was found to aggregate in pa-
tients with FTLD due to PGRN mutations [18]. In agree-
ment with these reports, we found that increased SCMAS
aggregates in aged PGRN deficient mice compared to con-
trols (Fig. 6a, b). To examine lysosomal phenotypes more
carefully, we stained brain sections using anti-LAMP1 anti-
bodies. Consistent with previous reports [29], we found that
neuronal lysosomes in the adult mouse brain are typically
< 1 μm in size and are often situated in a perinuclear pos-
ition. Normal aging results in occasional enlarged lyso-
somes (>1 μm) but this phenotype is dramatically
exacerbated by PGRN deficiency (Fig. 7a-c). TMEM106B
overexpression causes lysosomal enlargement and dysfunc-
tion in cell culture [6, 7, 21]. Thus we examined whether
increased TMEM106B levels in the PGRN−/− mice due to
transgene expression would lead to enhanced lysosomal
dysfunction and lipofuscin accumulation. While the expres-
sion of TMEM106B transgene does not result in lipofuscin
accumulation or any abnormal lysosomal morphology in
the wild type mice, it significantly increased the amount of
autofluorescence signals as an indicator of lipofuscin depos-
ition (Fig. 5a-c), SCMAS accumulation (Fig. 6a and b) and
the percentage of neurons with enlarged lysosomes in the
PGRN deficient mice upon aging (Fig. 7a-c). SCMAS sig-
nals are colocalized with lysosomal markers LAMP1 and
cathepsin D, indicating SCMAS aggregates are in the lyso-
somes (Additional file 3). Moreover, the levels of
TMEM106B proteins seem correlated with the extent of
lysosomal enlargement (Fig. 7a). These results clearly dem-
onstrate that elevated TMEM106B levels exacerbate lyso-
somal pathology caused by PGRN loss and explain how
TMEM106B risk alleles resulting in increased TMEM106B
levels serve as the risk factor for FTLD with PGRN
mutations.
Discussion
In this study we generated transgenic mice expressing hu-
man TMEM106B cDNA under the neuronal specific pro-
moter CamKII. The expression of human transgene was
confirmed by qPCR at the RNA level and by mass spec-
trometry analysis at the protein level. However, despite
the expression of the transgene, the total protein level of
TMEM106B in the cortex of the young mice is not chan-
ged, suggesting a tight regulation of TMEM106B protein
levels in neurons. Our data further showed that PGRN is
one of the key mechanisms that promotes TMEM106B
turnover in the aged brain.
Multiple studies have suggested a critical role of
TMEM106B in regulating lysosomal function [6, 7,
20, 21, 36] and elevated TMEM106B levels are associated
with increased risk for FTLD-TDP with PGRN mutations
[10, 15, 41, 43]. Since proper lysosomal function is critical
towards preventing neurodegeneration, it is not surprising
that TMEM106B levels are tightly regulated to ensure
proper lysosomal activities. Indeed, TMEM106B protein is
a substrate for lysosomal degradation [6, 7, 21]. Thus
healthy lysosomes are able to maintain proper TMEM106B
levels through their own degradative activities.
Loss of PGRN results in NCL in humans [35] and in-
creased accumulation of lipofuscin in mice during aging
[1, 38]. We also demonstrated that PGRN is a lysosomal
resident protein [19, 46]. However, the precise function
of PGRN in the lysosome is still unknown. Our data
support that at least one function of PGRN is to pro-
mote TMEM106B degradation to maintain the proper
level of TMEM106B on lysosomal membranes in the
aged brain. How PGRN performs this action, though, re-
mains unknown. One possibility is that PGRN helps
maintain the proper activity of lysosomal enzymes dur-
ing aging. In addition to TMEM106B, other lysosomal
substrates accumulate in response to PGRN deficiency.
SCMAS and saposin D, components of the lipofuscin,
aggregate in PGRN−/− mouse brain and FTLD-PGRN
patient samples (Fig. 6) [18]. It remains to be determined
whether PGRN plays a direct role in TMEM106B turn-
over or indirectly by regulating lysosomal functions.
Fig. 4 Expression of the TMEM106B transgene results in elevated
TMEM106B levels in aged PGRN−/− mice. a Transgene expression does
not lead to changes in TMEM106B protein levels in young PGRN−/−
mice of 4–5 months old compared to littermate WT controls. Cortical
lysates from the transgenic and littermate controls were subjected to
Western blot with anti- TMEM106B antibodies. b TMEM106B transgene
expression leads to increased TMEM106B protein levels in aged PGRN
−/−mice (17-20 months old). n = 3, student’s t-test. *, p < 0.05; ns,
no significance
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Fig. 5 TMEM106B transgene expression increases lipofuscin accumulation in PGRN deficient mice. a TMEM106B transgene expression results in
increased autofluorescence in the cortex and thalamus in PGRN-/- mice but has no effect on WT mice. Brain sections from 17-20 months old mice of
indicated genotypes were imaged at 594nm for auto fluorescent signals (red). The auto fluorescent signals were quantified by Image J. Hochest 33324
was used as a marker for nuclei (blue). Scale bar=100 μm (b, c) Quantification of (a). n=3, student’s t-test, **, p<0.01; ***, p<0.001; ns, no significance
Fig. 6 TMEM106B transgene expression increases SCMAS aggregation in PGRN deficient mice. Brain sections (a, cortex; b, thalamus) from 17-
20months old mice of indicated genotypes were stained with anti-SCMAS and anti-cathepsin D antibodies. Scale bar = 40 μm
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TDP-43 aggregation and hyper-phosphorylation is a
hallmark for FTLD with PGRN mutations [4, 11, 17].
However, we failed to detect TDP-43 pathology in our
PGRN deficient mice with or without TMEM106B
transgene overexpression (data not shown). Thus the
FTLD pathology is not fully recapitulated in mouse
models.
Nevertheless, we have generated a transgenic
model for TMEM106B function in FTLD. Our mouse
model closely mimics the interplay between PGRN
and TMEM106B during FTLD progression. First,
much like in human patients, the increase of
TMEM106B protein levels from the transgene ex-
pression is much more evident in PGRN deficient
mice, suggesting a regulation of TMEM106B levels
by PGRN. Second, TMEM106B transgene expression
only affects lysosomal morphology and lipofuscin de-
position in a PGRN deficient background, closely
mimicking human cases in which TMEM106B has
been identified as a risk factor for FTLD with PGRN
mutations. Third, the effect of PGRN on TMEM106B
turnover and proper lysosomal function is much
more evident in the aged brain, consistent with no-
tions that aging is the biggest risk factor for neuro-
degenerative diseases and lysosomal function declines
with age. Our data led us to propose a model on the
relationship between PGRN, TMEM106B, lysosomes
and FTLD (Fig. 8). TMEM106B protein levels are
tightly regulated through lysosomal activities. In
healthy adults, increased TMEM106B protein pro-
duction due to the transgene expression or from
TMEM106B risk allele is quickly balanced by in-
creased lysosomal degradation of TMEM106B, result-
ing in normal TMEM106B levels. However, this
regulation of TMEM106B levels is disrupted by
PGRN mutations, which results in lysosomal dys-
function coupled with aging. Consequently
TMEM106B levels are elevated in PGRN deficient
background in the aged brain. This increase in
TMEM106B levels further exacerbates lysosomal
Fig. 7 TMEM106B transgene expression exacerbates lysosomal abnormalities in PGRN deficient mice. a TMEM106B transgene expression results in more
lysosomal enlargement in PGRN−/−mice but has no effect on WT mice. Brain sections from 17-20 month old mice of indicated genotypes were stained
with anti-TMEM106B, anti-LAMP1 and anti-cathepsin D antibodies. Neurons from layer III-V cortical regions were shown as examples. Scale bar = 20 μm
(inset: 2 μm) (b) Percentage of neurons containing enlarged lysosomes (>1 μm) were quantified for experiment in (a). c Percentage of neurons containing
more than 10 enlarged lysosomes (>1 μm) were quantified for experiment in (a). n = 3, one-way ANOVA, *, p < 0.05; ***, p < 0.001; ns, no significance
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dysfunction, leading to increased lysosomal enlarge-
ment and lipofuscin accumulation, and also a further
increase in TMEM106B levels. This positive feedback
loop eventually leads to loss of lysosomal function
and neuronal death with aging.
A portion of FTLD patients also develop amyo-
trophic lateral sclerosis (ALS) phenotypes (FTLD/
ALS). Hexanucleotide repeat expansion in the intron
region of the C9orf72 gene, are responsible for the
majority cases of FTLD/ALS with TDP-43 aggregates
[12, 30, 44]. Recently TMEM106B polymorphisms
have been shown to modify the disease phenotypes in
FTLD/ALS cases with repeat expansions in the
C9orf72 gene [16, 22, 40]. C9orf72 might also be in-
volved in endolysosomal trafficking and autophagy-
lysosome pathway [2, 8, 14, 27, 34, 37, 39, 45].
TMEM106B is also implicated in pathological presen-
tation of Alzheimer’s disease [31] and lysosomal dys-
function has been shown to be implicated in
Alzheimer’s disease as well. Thus it will be interesting
to investigate whether lysosomal impairment in
FTLD/ALS/C9orf72 and AD cases could trigger the
imbalance in TMEM106B protein homeostasis that
leads to TMEM106B induced toxicity.
Conclusion
Our TMEM106B transgenic mouse model nicely reca-
pitulates the interaction between progranulin and
TMEM106B in human patients and support a regula-
tion of TMEM106B by progranulin in the aged brain
and a role of TMEM106B in FTLD-PGRN disease
progression.
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